Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer

Despite numerous reports on immune checkpoint inhibitor for the treatment of non-small cell lung cancer (NSCLC), the response rate remains low but durable. Thus cisplatin still plays a major role in the treatment of NSCLC. While there are many mechanisms involved in cisplatin resistance, alteration...

Descripción completa

Detalles Bibliográficos
Autores principales: Wangpaichitr, M, Kandemir, H, Li, YY, Wu, C, Nguyen, DJM, Feun, LG, Kuo, MT, Savaraj, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557290/
https://www.ncbi.nlm.nih.gov/pubmed/28819582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557290/
https://www.ncbi.nlm.nih.gov/pubmed/28819582

Ejemplares similares